Sanofi says Genzyme won't hit first milestone in CVR deal

07/28/2011 | Reuters

Sanofi said it doesn't expect Genzyme to receive its first milestone fees under a contingent-value right agreement due to the company's inability to resume normal supply of Fabrazyme, one of its key drugs for rare diseases. "To return to normal supply levels of Fabrazyme for existing and new patients, the use of extra capacity at Genzyme's new manufacturing plant in Framingham, Mass., is required," the company announced.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Director of ASO Department
Bluegrass Family Health
Lexington-or could be in Nashville, TN, KY
Claims Director
Springfield, OR
Mgr NGS Provider Enrollment (I)
National Government Services - WellPoint
Harrisburg, PA
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA